24447861|t|Kampo medicine for palliative care in Japan.
24447861|a|Kampo medicines are currently manufactured under strict quality controls. The Ministry of Health, Labour and Welfare of Japan has approved 148 Kampo formulas. There is increasing evidence for the efficacy of Kampo medicines, and some are used clinically for palliative care in Japan. The specific aim of this review is to evaluate the clinical use of Kampo medicines in palliative care in the treatment of cancer. The conclusions are as follows: Juzentaihoto inhibits the progression of liver tumors in a dose-dependent manner and contributes to long-term survival. Hochuekkito has clinical effects on cachexia for genitourinary cancer and improves the QOL and immunological status of weak patients, such as postoperative patients. Daikenchuto increases intestinal motility and decreases the postoperative symptoms of patients with total gastrectomy with jejunal pouch interposition, suppresses postoperative inflammation following surgery for colorectal cancer, and controls radiation-induced enteritis. Rikkunshito contributes to the amelioration of anorectic conditions in cancer cachexia-anorexia syndrome. Goshajinkigan and Shakuyakukanzoto reduce the neurotoxicity of patients with colorectal cancer who undergo oxaliplatin and FOLFOX (5-fluorouracil/folinic acid plus oxaliplatin) therapy. Hangeshashinto has the effect of preventing and alleviating diarrhea induced by CPT-11(irinotecan) and combination therapy with S-1/CPT-11. O'rengedokuto significantly improves mucositis caused by anticancer agents. 
24447861	451	457	cancer	Disease	MESH:D009369
24447861	532	544	liver tumors	Disease	MESH:D008113
24447861	647	655	cachexia	Disease	MESH:D002100
24447861	660	680	genitourinary cancer	Disease	MESH:D014565
24447861	735	743	patients	Species	9606
24447861	767	775	patients	Species	9606
24447861	863	871	patients	Species	9606
24447861	940	966	postoperative inflammation	Disease	MESH:D007249
24447861	989	1006	colorectal cancer	Disease	MESH:D015179
24447861	1039	1048	enteritis	Disease	MESH:D004751
24447861	1121	1136	cancer cachexia	Disease	MESH:D009369
24447861	1137	1154	anorexia syndrome	Disease	MESH:D000855
24447861	1202	1215	neurotoxicity	Disease	MESH:D020258
24447861	1219	1227	patients	Species	9606
24447861	1233	1250	colorectal cancer	Disease	MESH:D015179
24447861	1263	1274	oxaliplatin	Chemical	MESH:D000077150
24447861	1279	1285	FOLFOX	Chemical	MESH:C410216
24447861	1287	1301	5-fluorouracil	Chemical	MESH:D005472
24447861	1302	1314	folinic acid	Chemical	MESH:D002955
24447861	1320	1331	oxaliplatin	Chemical	MESH:D000077150
24447861	1402	1410	diarrhea	Disease	MESH:D003967
24447861	1422	1428	CPT-11	Chemical	MESH:D000077146
24447861	1429	1439	irinotecan	Chemical	MESH:D000077146
24447861	1470	1473	S-1	Chemical	-
24447861	1474	1480	CPT-11	Chemical	MESH:D000077146
24447861	1519	1528	mucositis	Disease	MESH:D052016
24447861	1539	1549	anticancer	Chemical	-
24447861	Positive_Correlation	MESH:D000077146	MESH:D003967
24447861	Negative_Correlation	MESH:D000077150	MESH:D015179
24447861	Negative_Correlation	MESH:C410216	MESH:D015179
24447861	Positive_Correlation	MESH:C410216	MESH:D020258
24447861	Cotreatment	MESH:C410216	MESH:D000077150
24447861	Positive_Correlation	MESH:D000077150	MESH:D020258
24447861	Negative_Correlation	MESH:D005472	MESH:D015179
24447861	Cotreatment	MESH:D000077150	MESH:D002955
24447861	Positive_Correlation	MESH:D005472	MESH:D020258
24447861	Cotreatment	MESH:D000077150	MESH:D005472
24447861	Negative_Correlation	MESH:D002955	MESH:D015179

